Spain - Chronic Lymphocytic Leukemia | International Cancer Genome Consortium

Spain

Chronic Lymphocytic Leukemia - CLL with mutated and unmutated IgVH

Project Website HTML

;

Funding Organizations

Spain:	Institute of Health Carlos III

Spain:	Spanish Ministry of Science and Innovation

Research Organizations

Research Activities

Publication Policy

1:	ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML
2:	Template Letters to Facilitate Communications HTML to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors

Clinic & Pathology

Consent and Data Access:
Spain:	University of Deusto
Epidemiology:
Spain:	Catalan Institute of Oncology
Tissues and Clinical Annotation:
Spain:	Center for Cancer Research, University Hospital
	Hospital Clinic of Barcelona
	University of Barcelona

Consent and data access
The sample collection is done following the guidelines of the ICGC and the Spanish law on Biomedical Research. A working group has been established to study and define the appropriateness of the CLL project to these ethical and legal guidelines. The work of the Bioethical working group includes the following tasks:
• Informed consent in retrospective and prospective samples
• Access to biological samples and data
• Intellectual Property

Epidemiology
• Evaluate epidemiological criteria in the selection of patients and gather personal and environmental information.

Tissues and clinical annotation
The clinical working group's main purpose is to:
• Define the criteria for selecting patients according to the overall project goals.
• Define and obtain clinical, pathologic, molecular and genetic information of patients.
• Standardize the storage process (Quality Assurance, Quality Control, SOPs, and Traceability).
• Diagnose, according to the WHO classification and by an expert panel of pathologists and haematologists, the samples included in the project.
• Identify the type of samples needed for the project and the requirements of biomolecules, cells and tissues.

1:	ICGC CLL Project Consent Form PDF
2:	ICGC CLL Project Patient Brochure PDF
3:	ICGC CLL Project Epidemiology Questionnaire PDF

Sequencing & Analysis

Spain:	Center for Genomic Regulation
	Centro Nacional de Análisis Genómico
	University of Oviedo

The Sequencing and Analysis working group focuses on:
• Molecular design of the study
• Technological development of genomic analysis
• Whole genome sequences
• Transcriptome sequences
• Exome capture and sequencing
• Analysis of genomic data generated by using Paired End sequencing and RNAseq.

Complementary Studies

Spain:	Center for Genomic Regulation
	Hospital Clinic of Barcelona
	Spanish National Cancer Research Centre
	University of Santiago de Compostela

Samples selected for sequencing studies are also included in complementary investigations such as transcriptome analysis, DNA Copy number alterations and massive genotyping using Affymetrix, Agilent and Illumina’s platforms. Methylome analysis will be also included in the project.

Data Storage, Analysis & Management

Spain:	Barcelona Supercomputing Centre
	Center for Genomic Regulation
	Centro Nacional de Análisis Genómico
	Pompeu Fabra University
	Spanish National Cancer Research Centre

The main objective of this group is to coordinate the mechanisms to share and exploit the data generated by the Consortium.

Project Summary

Chronic Lymphocytic Leukemia (CLL) is one of the most frequent tumors in Western countries. CLL represents 35% of all leukemias with an incidence of 3-7 per 100.000 habitants and reaches 12-15/100.000 in people over 60 years. The disease is heterogeneous; there are patients who have a long clinical evolution with a stable disease whereas others follow a progressive course with a median survival of 5-8 years. This heterogeneity is due to the existence of two major molecular groups, characterized respectively by the presence or absence of somatic mutations in immunoglobulin genes. Different genetic alterations have been identified associated with particular clinical presentations and evolution. There is also evidence of genetic predisposition, but the initiating genetic alterations are largely unknown in both sporadic and inherited cases. Today, there is no curative therapy for CLL.

As a contributing member of the ICGC, the CLL Consortium will generate a comprehensive catalogue of genetic alterations in 500 independent tumors. Normal and tumour samples with highly purified tumor cell content (>95%) and normal samples with <5% tumor cell contamination will be included.

Working Plan
- Clinical Selection and follow-up
- Epidemiological survey
- Sample Collection and characterization
- DNA/RNA Isolation and Sample Storage
- Genomics Analyses
- Complementary studies
- Data Management and storage

Principal Investigators

Hospital Clinic of Barcelona (HCPB), University of Barcelona (UB)
Elías Campo (Scientific Coordinator)
Emili Montserrat
Pedro Jares
Marta Aymerich
Magda Pinyol
Maruja Rozman
Neus Villamor
Silvia Bea
Armando Lopez-Guillermo
Dolors Colomer
Laura Conde
Roberto Alonso

University of Oviedo (UniOvi), University Institute of Oncology (IUOPA)
Carlos López-Otín (Co-coordinator)
Xose S. Puente
Victor Quesada
Gonzalo R. Ordóñez

Catalan Institute of Oncology (ICO)
Silvia San José

Center for Genomic Regulation (CRG)
Xavier Estivill
Roderic Guigó
Heinz Himmelbauer

Center for Cancer Research (CIC-Salamanca), University Hospital
Jesús San Miguel
Enrique de Álava
Marcos González-Díaz
Jesús M. Hernández-Rivas

University of Deusto (DEUSTO)
Pilar Nicolás
Carlos Romeo

National Cancer Research Centre (CNIO)
Miguel A. Piris
Alfonso Valencia
Javier Benítez

University of Santiago de Compostela (USC)
Ángel Carracedo

Barcelona Supercomputing Centre (BSC)
Modesto Orozco

Pompeu Fabra University (UPF)
Nuria López-Bigas

Centro Nacional de Análisis Genómico (CNAG)
Ivo Gut
Simon Heath
Marta Gut
Mónica Bayes
Sergi Beltran

International Cancer Genome Consortium

Tumor Type

Lead Jurisdiction